anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Donkey's milk is similar to human milk for its lactose, proteins, minerals, and amino-acid content. In terms of energy, donkey milk has a high lactose content but a low average fat content. To use it in infant nutrition before weaning, donkey milk should be fortified with a source of fat (sunflower oil); particular attention must also be given to essential fatty acids. Omega‐3 and omega‐6 fatty acids, particularly docosahexaenoic acid (DHA), are known to play an essential role in the development of the brain and retina. Intakes in pregnancy and early life affect growth and cognitive performance later in childhood, ensuring adequate intakes of fat, essential fatty acids, and DHA through these life stages is crucial. Cost-effective dietary sources of these fatty acids are needed to ensure adequate essential fatty acid and DHA intakes in these populations. The integration of these substances can take place with supplements of essential fatty acids (omega-3; omega-6) and vegetable oil certified for babies. It is important to exclude spores that can pass the gastric mucosa in the first 4 months. For children who are not allergic to cow or goat milk, a part of the fat can be compensated naturally by adding 1–2% of cow or goat butter. In any case, the integration of fats and essential fats can be done through the integration of donkey milk with artificial formulas for infants. From the point of view of hygienic-sanitary safety, like all milk, donkey milk and its ingredients must be pasteurized before taking.
The first fully virtual court hearing of a capital case was made via Zoom on 23 April 2020, when the Court of Appeal acquitted 27-year-old Singaporean drug suspect Mohammad Azli Mohammad Salleh and dismissed both his drug charge and his death sentence. There were originally two executions scheduled for drug traffickers Syed Suhail bin Syed Zin and Mohd Fadzir bin Mustaffa on 18 September 2020 and 24 September 2020 respectively, but they were subsequently postponed due to stays of execution granted pending last-minute appeals against the death sentences. As a result, there was no one executed in 2020. Similarly between January and October 2021, no new execution dates were set for the inmates on Singapore's death row, due to the ongoing COVID-19 pandemic and resurgence of community cases. The execution of Nagaenthran K. Dharmalingam was supposed to be carried out on 10 November 2021, but it was postponed due to Nagaenthran contracting COVID-19. The suspension of Nagaenthran's execution in 2021 also led to no executions being carried out in 2021 itself. There were originally two executions of Roslan Bakar and Pausi Jefridin to be carried out on 16 February 2022 and a third execution of Rosman Abdullah on 23 February 2022 before they were postponed due to the men's appeals. Due to the increasing notices of executions being revealed publicly, there were lingering concerns from civil groups and international figures that Singapore might resume executions to accommodate the growing death row inmate population at Changi Prison.
There are three agencies or organizations in the United States that collectively oversee physician board certification of MD and DO physicians in the United States in the 26 approved medical specialties recognized in the country. These organizations are the American Board of Medical Specialties (ABMS) and the American Medical Association (AMA); the American Osteopathic Association Bureau of Osteopathic Specialists (AOABOS) and the American Osteopathic Association; the American Board of Physician Specialties (ABPS) and the American Association of Physician Specialists (AAPS). Each of these agencies and their associated national medical organization functions as its various specialty academies, colleges and societies.
Sources: en.wikipedia.org
However, general purpose computer programs that are used to derive equilibrium constant values from experimental data use association constants for both acids and bases. Because stability constants for a metal-ligand complex are always specified as association constants, ligand protonation must also be specified as an association reaction. The definitions show that the value of an acid dissociation constant is the reciprocal of the value of the corresponding association constant:
==== The 12 nidanas in Mahāyāna sutras and tantras ==== Alex Wayman writes that Mahāyāna texts such as Śrīmālādevī Siṃhanāda Sūtra present an alternative interpretation of the twelve nidanas. According to Wayman, this interpretation holds that arhats, pratyekabuddhas, and bodhisattvas have eliminated the four kinds of clinging (nidana # 9), which are the usual condition for existence (or "gestation", nidana #10) and rebirth (#11) in one of the three realms. Instead of being reborn, they have a "body made of mind" (manōmaya kāya), which is a special consciousness (vijñana). This consciousness is projected by ignorance (nidana #1) and purified by a special kind of samskara (# 2) called "nonfluxional karma" (anāsrava-karma). These mind-made bodies produce a reflected image in the three worlds, and thus they appear to be born. According to Wayman, this view of dependent origination posits "a dualistic structure of the world, in the manner of heaven and earth, where the "body made of mind" is in heaven and its reflected image, or coarser equivalent, is on earth. Otherwise stated, the early members of Dependent Origination apply to the superior realm, the later members to the inferior realm. But the Śrī-mālā-Sūtra does not clarify how those members are allotted to their respective realms." According to Wayman, similar interpretations appear in tantric texts, such as the Caṇḍamahāroṣaṇatantra.
The fifth and final single from the album, "Zzyzx Rd.", started receiving radio airplay in fall 2007; no music video was made for the single. The band began touring in support of the album before its release, starting with several free shows in the US, followed by appearances at festivals in Europe. They then joined Korn for their 2006 edition of Family Values Tour across the US, with 33 dates across 3 months. On August 8, 2006, Stone Sour made a special guest appearance on The Tonight Show with Jay Leno to promote and perform the second single, "Through Glass." They also performed at the Japanese Summer Sonic Festival midway through the Family Values Tour. In November and December 2006, Stone Sour joined Disturbed for their Music as a Weapon Tour. In January 2007, Stone Sour joined Evanescence for a Canadian tour, followed by a headlining tour of Europe. They then headlined the spring 2007 Jägermeister Music Tour across the US, followed by headlining tours in Australia and Japan. They then started a tour in Europe playing at festivals and selected headline shows. They finished touring in support of the album with a headlining tour in the US in August and September in 2007.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.